CoChat

H3K9me3-mediated epigenetic regulation of senescence in mice predicts outcome of lymphoma patients

Open access
Schleich, Kolja, Kase, Julia, Dörr, Jan R., Trescher, Saskia, Bhattacharya, Animesh, Yu, Yong, Wailes, Elizabeth M., Fan, Dorothy N. Y., Lohneis, Philipp, Milanovic, Maja, Lau, Andrea, Lenze, Dido, Hummel, Michael, Chapuy, Bjoern, Leser, Ulf, Reimann, Maurice, Lee, Soyoung, Schmitt, Clemens A. · 2020 · Nature Communications
Cited by 32

The DOI matches its Crossref record; 23 of the 23 references it cites were found in a registry or an index.

Abstract

Lesion-based targeting strategies underlie cancer precision medicine. However, biological principles – such as cellular senescence – remain difficult to implement in molecularly informed treatment decisions. Functional analyses in syngeneic mouse models and cross-species validation in patient datasets might uncover clinically relevant genetics of biological response programs. Here, we show that chemotherapy-exposed primary Eµ-myc transgenic lymphomas – with and without defined genetic lesions – recapitulate molecular signatures of patients with diffuse large B-cell lymphoma (DLBCL). Importantly, we interrogate the murine lymphoma capacity to senesce and its epigenetic control via the histone H3 lysine 9 (H3K9)-methyltransferase Suv(ar)39h1 and H3K9me3-active demethylases by loss- and gain-of-function genetics, and an unbiased clinical trial-like approach. A mouse-derived senescence-indicating gene signature, termed “SUVARness”, as well as high-level H3K9me3 lymphoma expression, predict favorable DLBCL patient outcome. Our data support the use of functional genetics in transgenic mouse models to incorporate basic biology knowledge into cancer precision medicine in the clinic.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1038/s41467-020-17467-z

Cites

23 of 23 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 23 references

Research works printed but not linked: 47

  1. deVita VT, Hellman S, Rosenberg SA. Cancer: Principles And Practice Of Oncology, 6 edn. (Lippincott Williams & Wilkins, 2001).
  2. McKelvey, E. M. et al. Hydroxyldaunomycin (Adriamycin) combination chemotherapy in malignant lymphoma. Cancer 38, 1484–1493 (1976). · DOI · Paper page
  3. Coiffier, B. et al. CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. N. Engl. J. Med. 346, 235–242 (2002). · DOI · Paper page
  4. Tilly, H. et al. Diffuse large B-cell lymphoma (DLBCL): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann. Oncol. 26(Suppl 5), v116–125 (2015). · DOI · Paper page
  5. Gisselbrecht, C. et al. Salvage regimens with autologous transplantation for relapsed large B-cell lymphoma in the rituximab era. J. Clin. Oncol. 28, 4184–4190 (2010). · DOI · Paper page
  6. Alizadeh, A. A. et al. Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling. Nature 403, 503–511 (2000). · DOI · Paper page
  7. Hummel, M. et al. A biologic definition of Burkitt’s lymphoma from transcriptional and genomic profiling. N. Engl. J. Med. 354, 2419–2430 (2006). · DOI · Paper page
  8. Lenz, G. et al. Stromal gene signatures in large-B-cell lymphomas. N. Engl. J. Med. 359, 2313–2323 (2008). · DOI · Paper page
  9. Pasqualucci, L. et al. Analysis of the coding genome of diffuse large B-cell lymphoma. Nat. Genet. 43, 830–837 (2011). · DOI · Paper page
  10. Lohr, J. G. et al. Discovery and prioritization of somatic mutations in diffuse large B-cell lymphoma (DLBCL) by whole-exome sequencing. Proc. Natl Acad. Sci. USA 109, 3879–3884 (2012). · DOI · Paper page
  11. Zhang, J. et al. Genetic heterogeneity of diffuse large B-cell lymphoma. Proc. Natl Acad. Sci. USA 110, 1398–1403 (2013). · DOI · Paper page
  12. Yu, M. et al. Cancer therapy. Ex vivo culture of circulating breast tumor cells for individualized testing of drug susceptibility. Science 345, 216–220 (2014). · DOI · Paper page
  13. Pauli, C. et al. Personalized in vitro and in vivo cancer models to guide precision medicine. Cancer Discov. 7, 462–477 (2017). · DOI · Paper page
  14. Schmitt, C. A., Rosenthal, C. T. & Lowe, S. W. Genetic analysis of chemoresistance in primary murine lymphomas. Nat. Med. 6, 1029–1035 (2000). · DOI · Paper page
  15. Schmitt, C. A., Yang, M., Fridman, J. S., Baranov, E., Hoffman, R. M. & Lowe, S. W. Dissecting p53 tumor suppressor functions in vivo. Cancer Cell 1, 289–298 (2002). · DOI · Paper page
  16. Reimann, M. et al. The Myc-evoked DNA damage response accounts for treatment resistance in primary lymphomas in vivo. Blood 110, 2996–3004 (2007). · DOI · Paper page
  17. Jing, H. et al. Opposing roles of NF-κB in anti-cancer treatment outcome unveiled by cross-species investigations. Genes Dev. 25, 2137–2146 (2011). · DOI · Paper page
  18. Chan, A. S. L. & Narita, M. Short-term gain, long-term pain: the senescence life cycle and cancer. Genes Dev. 33, 127–143 (2019). · DOI · Paper page
  19. Lee, S. & Schmitt, C. A. The dynamic nature of senescence in cancer. Nat. Cell Biol. 21, 94–101 (2019). · DOI · Paper page
  20. Feugier, P. et al. Long-term results of the R-CHOP study in the treatment of elderly patients with diffuse large B-cell lymphoma: a study by the Groupe d’Etude des Lymphomes de l’Adulte. J. Clin. Oncol. 23, 4117–4126 (2005). · DOI · Paper page
  21. Pfreundschuh, M. et al. Six versus eight cycles of bi-weekly CHOP-14 with or without rituximab in elderly patients with aggressive CD20+ B-cell lymphomas: a randomised controlled trial (RICOVER-60). Lancet Oncol. 9, 105–116 (2008). · DOI · Paper page
  22. Compagno, M. et al. Mutations of multiple genes cause deregulation of NF-kappaB in diffuse large B-cell lymphoma. Nature 459, 717–721 (2009). · DOI · Paper page
  23. Rempel, R. E. et al. Utilization of the Emu-Myc mouse to model heterogeneity of therapeutic response. Mol. Cancer Ther. 13, 3219–3229 (2014). · DOI
  24. Dave, S. S. et al. Molecular diagnosis of Burkitt’s lymphoma. N. Engl. J. Med. 354, 2431–2442 (2006). · DOI · Paper page
  25. Wright, G. et al. A gene expression-based method to diagnose clinically distinct subgroups of diffuse large B cell lymphoma. Proc. Natl Acad. Sci. USA 100, 9991–9996 (2003). · DOI · Paper page
  26. Kluk, M. J. et al. Immunohistochemical detection of MYC-driven diffuse large B-cell lymphomas. PLoS ONE 7, e33813 (2012). · DOI · Paper page
  27. Monti, S. et al. Molecular profiling of diffuse large B-cell lymphoma identifies robust subtypes including one characterized by host inflammatory response. Blood 105, 1851–1861 (2005). · DOI · Paper page
  28. Varier, R. A. & Timmers, H. T. Histone lysine methylation and demethylation pathways in cancer. Biochim. Biophys. Acta 1815, 75–89 (2011).
  29. Kooistra, S. M. & Helin, K. Molecular mechanisms and potential functions of histone demethylases. Nat. Rev. Mol. Cell Biol. 13, 297–311 (2012). · DOI · Paper page
  30. Amente, S., Lania, L. & Majello, B. The histone LSD1 demethylase in stemness and cancer transcription programs. Biochim Biophys. Acta 1829, 981–986 (2013). · DOI · Paper page
  31. Berry, W. L. & Janknecht, R. KDM4/JMJD2 histone demethylases: epigenetic regulators in cancer cells. Cancer Res. 73, 2936–2942 (2013). · DOI · Paper page
  32. Hojfeldt, J. W., Agger, K. & Helin, K. Histone lysine demethylases as targets for anticancer therapy. Nat. Rev. Drug Discov. 12, 917–930 (2013). · DOI · Paper page
  33. Lord, C. J. & Ashworth, A. BRCAness revisited. Nat. Rev. Cancer 16, 110–120 (2016). · DOI · Paper page
  34. Xue, W. et al. Senescence and tumour clearance is triggered by p53 restoration in murine liver carcinomas. Nature 445, 656–660 (2007). · DOI · Paper page
  35. Mori, S. et al. Utilization of pathway signatures to reveal distinct types of B lymphoma in the Emicro-myc model and human diffuse large B-cell lymphoma. Cancer Res. 68, 8525–8534 (2008). · DOI · Paper page
  36. Weber, J. et al. PiggyBac transposon tools for recessive screening identify B-cell lymphoma drivers in mice. Nat. Commun. 10, 1415 (2019).
  37. O’Connor, T. et al. Age-Related Gliosis Promotes Central Nervous System Lymphoma through CCL19-Mediated Tumor Cell Retention. Cancer Cell 36, 250–267 e259 (2019). · DOI
  38. Cattoretti, G. et al. Targeted disruption of the S1P2 sphingosine 1-phosphate receptor gene leads to diffuse large B-cell lymphoma formation. Cancer Res. 69, 8686–8692 (2009). · DOI · Paper page
  39. Calado, D. P. et al. Constitutive canonical NF-kappaB activation cooperates with disruption of BLIMP1 in the pathogenesis of activated B cell-like diffuse large cell lymphoma. Cancer Cell 18, 580–589 (2010). · DOI · Paper page
  40. Zhang, B. et al. An oncogenic role for alternative NF-kappaB signaling in DLBCL revealed upon deregulated BCL6 expression. Cell Rep. 11, 715–726 (2015). · DOI
  41. Knittel, G. et al. B-cell-specific conditional expression of Myd88p.L252P leads to the development of diffuse large B-cell lymphoma in mice. Blood 127, 2732–2741 (2016). · DOI · Paper page
  42. Takahara, T., Matsuo, K., Seto, M., Nakamura, S. & Tsuzuki, S. Synergistic activity of Card11 mutant and Bcl6 in the development of diffuse large B-cell lymphoma in a mouse model. Cancer Sci. 107, 1572–1580 (2016). · DOI
  43. Garcia-Ramirez, I. et al. Crebbp loss cooperates with Bcl2 overexpression to promote lymphoma in mice. Blood 129, 2645–2656 (2017). · DOI · Paper page
  44. Zhang, J. et al. The CREBBP acetyltransferase is a haploinsufficient tumor suppressor in B-cell lymphoma. Cancer Discov. 7, 322–337 (2017). · DOI · Paper page
  45. Caeser, R. et al. Genetic modification of primary human B cells to model high-grade lymphoma. Nat. Commun. 10, 4543 (2019). · DOI
  46. Pascual, M. et al. PD-1/PD-L1 immune checkpoint and p53 loss facilitate tumor progression in activated B-cell diffuse large B-cell lymphomas. Blood 133, 2401–2412 (2019). · DOI · Paper page
  47. Hochberg, Y. & Benjamini, Y. More powerful procedures for multiple significance testing. Stat. Med. 9, 811–818 (1990). · DOI · Paper page

Cited by

See all 32

Metadata

Authors
Schleich, K., Kase, J., Dörr, J. R., Trescher, S., Bhattacharya, A., Yu, Y., Wailes, E. M., Fan, D. N. Y., Lohneis, P., Milanovic, M., Lau, A., Lenze, D., Hummel, M., Chapuy, B., Leser, U., Reimann, M., Lee, S., & Schmitt, C. A.
Venue
Nature Communications
Published
2020-07-20
Volume
11
Issue
1
Pages
3651-3651
ISSN
2041-1723 (ISSN-L)
OpenAlex
W3043339790
Cited by
32
References
23
FWCI
1.76
Type
journal article
Language
en
Open access
gold
Licence

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: H3K9me3-mediated epigenetic regulation of senescence in mice predicts outcome of lymphoma patients. https://app.cochat.ai/papers/10.1038/s41467-020-17467-z
The paper
Schleich, K., Kase, J., Dörr, J. R., Trescher, S., Bhattacharya, A., Yu, Y., Wailes, E. M., Fan, D. N. Y., Lohneis, P., Milanovic, M., Lau, A., Lenze, D., Hummel, M., Chapuy, B., Leser, U., Reimann, M., Lee, S., & Schmitt, C. A. (2020). H3K9me3-mediated epigenetic regulation of senescence in mice predicts outcome of lymphoma patients. Nature Communications. https://doi.org/10.1038/s41467-020-17467-z

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.